Revolution Medicines has given its first public look at the early-stage data that convinced it to advance a combination of two KRAS drugs into late-stage testing.
According to Endpoints News, the company shared the promising results on Thursday. The data underpin its plan to launch a Phase 3 trial that pairs two of its KRAS-targeting drugs in patients with pancreatic cancer.
KRAS refers to one of the most common genetic drivers found in human cancers, and drugs aimed at it have become a closely watched area of oncology research. Rather than testing a single medicine, Revolution Medicines is pursuing a combination approach, using two drugs together against the disease.
A Phase 3 trial is the large, pivotal stage of clinical testing that companies must generally clear before seeking regulatory approval. The decision to move a drug combination into that phase signals that the earlier results were encouraging enough to justify a bigger, more expensive study.
Endpoints News noted that Thursday's disclosure marked the first detailed view of those early results, though the fuller specifics of the two drugs and the trial were still emerging.
Why it matters: pancreatic cancer is one of the hardest cancers to treat, so credible progress on a new drug combination aimed at a key cancer driver could matter for patients with few good options.